0001562180-20-005001.txt : 20200706 0001562180-20-005001.hdr.sgml : 20200706 20200706175034 ACCESSION NUMBER: 0001562180-20-005001 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200701 FILED AS OF DATE: 20200706 DATE AS OF CHANGE: 20200706 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Llewelyn Linda CENTRAL INDEX KEY: 0001780878 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38993 FILM NUMBER: 201014483 MAIL ADDRESS: STREET 1: C/O HEALTH CATALYST, INC. STREET 2: 3165 E. MILLROCK DRIVE #400 CITY: SALT LAKE CITY STATE: UT ZIP: 84121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Health Catalyst, Inc. CENTRAL INDEX KEY: 0001636422 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMPUTER PROGRAMMING, DATA PROCESSING, ETC. [7370] IRS NUMBER: 453337483 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3165 E. MILLROCK, SUITE 400 CITY: SALT LAKE CITY STATE: UT ZIP: 84121 BUSINESS PHONE: 801-708-6800 MAIL ADDRESS: STREET 1: 3165 E. MILLROCK, SUITE 400 CITY: SALT LAKE CITY STATE: UT ZIP: 84121 FORMER COMPANY: FORMER CONFORMED NAME: HQC Holdings, Inc. DATE OF NAME CHANGE: 20150312 4 1 primarydocument.xml PRIMARY DOCUMENT X0306 4 2020-07-01 false 0001636422 Health Catalyst, Inc. HCAT 0001780878 Llewelyn Linda C/O HEALTH CATALYST, INC. 3165 MILLROCK DRIVE, #400 SALT LAKE CITY UT 84121 false true false false Chief People Officer Common Stock 2020-07-01 4 M false 2242.00 10.80 A 27619.00 D Common Stock 2020-07-01 4 S false 1021.00 28.77 D 26598.00 D Common Stock 2020-07-01 4 S false 1221.00 29.97 D 25377.00 D Stock Option (Right to Buy) 10.80 2020-07-01 4 M false 2242.00 0.00 D 2028-09-27 Common Stock 2242.00 32439.00 D The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on November 21, 2019, in accordance with Rule 10b5-1. Represents a weighted average price. These shares were sold by the Reporting Person in multiple transactions at prices ranging from $28.52 to $29.42, inclusive. Represents a weighted average price. These shares were sold by the Reporting Person in multiple transactions at prices ranging from $29.74 to $30.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnotes (2) and (3). 25% of the 59,351 shares underlying the options vested in an annual installment on September 25, 2019 and the remaining balance vested or will vest in equal monthly installments until the option is vested in full on September 25, 2022. /s/ Daniel Orenstein, as Attorney-in-Fact 2020-07-06